| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2131* | 2021 |
| Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI BC Blount, MP Karwowski, PG Shields, M Morel-Espinosa, ... New England Journal of Medicine 382 (8), 697-705, 2020 | 774 | 2020 |
| Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial P Ponikowski, BA Kirwan, SD Anker, T McDonagh, M Dorobantu, ... The Lancet 396 (10266), 1895-1904, 2020 | 630 | 2020 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 459* | 2021 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 345 | 2022 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 256 | 2022 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 252 | 2022 |
| Acute heart failure congestion and perfusion status–impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure … O Chioncel, A Mebazaa, AP Maggioni, VP Harjola, G Rosano, C Laroche, ... European journal of heart failure 21 (11), 1338-1352, 2019 | 252 | 2019 |
| Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded … PR Kalra, JGF Cleland, MC Petrie, EA Thomson, PA Kalra, IB Squire, ... The Lancet 400 (10369), 2199-2209, 2022 | 233 | 2022 |
| The Type IA supernova 1989B in NGC 3627 (M66) LA Wells, MM Phillips, B Suntzeff, SR Heathcote, M Hamuy, M Navarrete, ... Astronomical Journal (ISSN 0004-6256), vol. 108, no. 6, p. 2233-2250 108 …, 1994 | 206 | 1994 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 200 | 2021 |
| The surgical safety checklist and patient outcomes after surgery: a prospective observational cohort study, systematic review and meta-analysis TEF Abbott, T Ahmad, MK Phull, AJ Fowler, R Hewson, BM Biccard, ... British journal of anaesthesia 120 (1), 146-155, 2018 | 170 | 2018 |
| Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure Long-Term Registry M Canepa, C Fonseca, O Chioncel, C Laroche, MG Crespo-Leiro, ... JACC: Heart Failure 6 (6), 452-462, 2018 | 145 | 2018 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial SY Rha, DY Oh, P Yañez, Y Bai, MH Ryu, J Lee, F Rivera, GV Alves, ... The Lancet Oncology 24 (11), 1181-1195, 2023 | 116 | 2023 |
| Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA … P Rossignol, M Lainscak, MG Crespo‐Leiro, C Laroche, MF Piepoli, ... European journal of heart failure 22 (8), 1378-1389, 2020 | 115 | 2020 |
| Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 109 | 2022 |
| Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis IA McNeish, R Lopes, SJ Bell, TR McKay, M Fernandez, M Lockley, ... Experimental cell research 302 (1), 69-82, 2005 | 109 | 2005 |
| Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... Jama 329 (1), 39-51, 2023 | 102 | 2023 |
| Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability RH Reynolds, J Botía, MA Nalls, J Hardy, SA Gagliano Taliun, M Ryten npj Parkinson's Disease 5 (1), 6, 2019 | 91 | 2019 |
| SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 83 | 2023 |
